Litcius/Paper detail

968P Neoadjuvant nivolumab (N) plus weekly carboplatin (C) and paclitaxel (P) outcomes in HPV(-) resectable locally advanced head and neck cancer

Ralph Zinner, Jennifer M. Johnson, Madalina Tuluc, Joseph Curry, Adam Luginbuhl, Christopher Fundakowski, Andrew Yampolsky, Richard A. Goldman, Charalambos Solomides, Stacey K. Mardekian, C. Tuckey, Grace Lu‐Yao, Larry A. Harshyne, Dorit Arditti-Falk, Dawn Poller, Benjamin E. Leiby, Voichita Bar‐Ad, R. Axelrod, Athanassios Argiris, David M. Cognetti

2020Annals of Oncology14 citationsDOI

Topics & Concepts

MedicineClinical endpointInternal medicineOncologyRegimenPrimary tumorCarboplatinNivolumabCancerStage (stratigraphy)SurgeryMetastasisChemotherapyClinical trialCisplatinImmunotherapyPaleontologyBiologyHead and Neck Cancer StudiesCancer Diagnosis and TreatmentCancer Immunotherapy and Biomarkers
968P Neoadjuvant nivolumab (N) plus weekly carboplatin (C) and paclitaxel (P) outcomes in HPV(-) resectable locally advanced head and neck cancer | Litcius